Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination therapy of Eicosapentaenoic acid and pitavastatin for Regression of coronary plaque evaluated by integrated backscatter intravascular ultrasonography; CHERRY study.

Next Previous
Search
Trial Profile

Combination therapy of Eicosapentaenoic acid and pitavastatin for Regression of coronary plaque evaluated by integrated backscatter intravascular ultrasonography; CHERRY study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ethyl eicosapentaenoic acid (Primary) ; Pitavastatin (Primary)
  • Indications Acute coronary syndromes; Angina pectoris; Atherosclerosis; Hyperlipidaemia
  • Focus Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms CHERRY

    • Most Recent Events

    • 17 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 09 Nov 2015 According to an Amarin Corporation media release, abstract of trial was published in Circulation.
    • 09 Nov 2015 According to an Amarin Corporation media release, results from this trial were presented at the American Heart Association Scientific Sessions.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top